← All drugs
Drug · FAERS side-effect profile with label screen

Tirzepatide side effects: what 160,620 FDA adverse event reports show

Tirzepatide · Mounjaro · 1,171 reaction terms · 336,013 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist, GLP-1 Receptor Agonist

FDA label (Established Pharmacologic Class)

Brand names

Mounjaro

openFDA label

Who reports

160,620 reports · 18% serious · 889 with death outcome · 76% female

openFDA FAERS counts, all years, deduplication not applied

Used for

MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor.

FDA label, Indications and Usage

What it is

MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains amino.

FDA label, Description section

Boxed warning

RISK OF THYROID C-CELL TUMORS In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO ca.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Labeled (related wording) 11Reporting / coding artifact 7Lab value / disease marker 1Not in label — unassessed 20
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,131 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug titration issue52316.4
190.6–525.3ROR 316.5 · calibrated p 8e-11 ✓
88.8 EB05 70.4 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=18 · 81% consumernot reported in cached trials
Intercepted product selection error553102.9
92.0–115.0ROR 103.2 · calibrated p 1e-7 ✓
57.3 EB05 53.4 · IC025 +5.6
3/3 methods agree
Not in label — unassessed98% consumernot reported in cached trials
Therapeutic response changed2,23172.9
69.2–76.8ROR 73.9 · calibrated p 1e-6 ✓
46.8 EB05 45.2 · IC025 +5.5
3/3 methods agree
Reporting / coding artifact100% consumernot reported in cached trials
Intercepted product dispensing error56369.3
62.6–76.8ROR 69.6 · calibrated p 2e-6 ✓
45.2 EB05 42.2 · IC025 +5.3
3/3 methods agree
Not in label — unassessed96% consumernot reported in cached trials
Accidental underdose4,60960.3
58.3–62.5ROR 62.1 · calibrated p 3e-6 ✓
41.3 EB05 40.3 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=25 · 98% consumernot reported in cached trials
Starvation ketoacidosis5451.9
37.8–71.2ROR 51.9 · calibrated p 2e-5 ✓
36.8 EB05 29.2 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=54NCT04255433: 1/6,647 (0.0%) on Tirzepatide (serious AE)
Product tampering46545.5
40.9–50.5ROR 45.6 · calibrated p 2e-5 ✓
33.8 EB05 31.3 · IC025 +4.9
3/3 methods agree
Reporting / coding artifactserious n=58 · 94% consumernot reported in cached trials
Extra dose administered9,60841.3
40.3–42.2ROR 43.8 · calibrated p 3e-5 ✓
31.4 EB05 30.9 · IC025 +4.9
3/3 methods agree
Not in label — unassessedage-adj. PRR 59.5 · serious n=142 · 97% consumernot reported in cached trials
Gastric hypomotility5730.1
22.6–40.2ROR 30.1 · calibrated p 3e-4 ✓
24.4 EB05 19.5 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=54 · 100% consumernot reported in cached trials
Gastrointestinal hypomotility36725.6
22.9–28.6ROR 25.6 · calibrated p 6e-4 ✓
21.4 EB05 19.7 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=348 · 95% consumerNCT04184622: 1/636 (0.2%) on Tirzepatide (serious AE)
Obstructive pancreatitis11824.8
20.4–30.3ROR 24.9 · calibrated p 8e-4 ✓
20.9 EB05 17.9 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=118 · 75% consumerNCT04255433: 6/6,647 (0.1%) on Tirzepatide (serious AE)
Eructation (belching)2,91323.5
22.6–24.4ROR 23.9 · calibrated p 8e-4 ✓
20.0 EB05 19.4 · IC025 +4.3
3/3 methods agree
Labeled adverse reaction
exact term
serious n=332 · 96% consumerNCT04255433: 359/6,647 (5.4%) on Tirzepatide
Allodynia15420.6
17.4–24.4ROR 20.6 · calibrated p 0.002 ✓
17.8 EB05 15.6 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=50 · 88% consumernot reported in cached trials
Incorrect dose administered29,67219.7
19.5–19.9ROR 24.0 · calibrated p 8e-4 ✓
17.2 EB05 17.1 · IC025 +4.1
3/3 methods agree
Reporting / coding artifactage-adj. PRR 26.1 · serious PRR 2.4 · 97% consumernot reported in cached trials
Hunger1,77219.7
18.7–20.7ROR 19.9 · calibrated p 0.002 ✓
17.2 EB05 16.5 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=49 · 98% consumernot reported in cached trials
Intercepted product prescribing error17019.6
16.7–23.0ROR 19.6 · calibrated p 0.002 ✓
17.1 EB05 15.0 · IC025 +3.8
3/3 methods agree
Not in label — unassessed95% consumernot reported in cached trials
Food craving63819.2
17.6–20.8ROR 19.2 · calibrated p 0.002 ✓
16.8 EB05 15.7 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=28 · 96% consumernot reported in cached trials
Skin laxity4716.8
12.4–22.7ROR 16.8 · calibrated p 0.005 ✓
14.8 EB05 11.5 · IC025 +3.2
3/3 methods agree
Not in label — unassessed♀ 100% (drug 76%) · 100% consumernot reported in cached trials
Acute cholecystitis necrotic2116.6
10.5–26.1ROR 16.6 · calibrated p 0.007 ✓
14.2 EB05 9.4 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=21 · 71% consumerNCT04255433: 2/6,647 (0.0%) on Tirzepatide (serious AE)
Incorrect product dosage form administered4415.9
11.6–21.8ROR 15.9 · calibrated p 0.007 ✓
14.1 EB05 10.8 · IC025 +3.1
3/3 methods agree
Reporting / coding artifact100% consumernot reported in cached trials
Lack of satiety2413.9
9.1–21.2ROR 13.9 · calibrated p 0.013 ✓
12.0 EB05 8.1 · IC025 +2.7
3/3 methods agree
Not in label — unassessed100% consumernot reported in cached trials
Duodenogastric reflux2412.6
8.3–19.1ROR 12.6 · calibrated p 0.018 ✓
10.8 EB05 7.3 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=15 · 83% consumernot reported in cached trials
Product administered at inappropriate site1,2569.6
9.1–10.2ROR 9.7 · calibrated p 0.036 ✓
9.0 EB05 8.6 · IC025 +3.1
3/3 methods agree
Reporting / coding artifactage-adj. PRR 15.6 · serious n=16 · 94% consumernot reported in cached trials
Accidental overdose2,0607.7
7.4–8.1ROR 7.8 · calibrated p 0.071
7.3 EB05 7.1 · IC025 +2.8
3/3 methods agree
Reporting / coding artifactage-adj. PRR 10.3 · serious PRR 0.6 · 97% consumerNCT04255433: 1/6,647 (0.0%) on Tirzepatide (serious AE)
Injury associated with device1,1337.7
7.3–8.2ROR 7.8 · calibrated p 0.072
7.3 EB05 7.0 · IC025 +2.8
3/3 methods agree
Not in label — unassessedage-adj. PRR 9.7 · 94% consumernot reported in cached trials
Vomiting projectile1617.7
6.6–9.1ROR 7.7 · calibrated p 0.075
7.2 EB05 6.3 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=82 · 95% consumernot reported in cached trials
Incorrect product formulation administered477.7
5.7–10.3ROR 7.7 · calibrated p 0.082
6.9 EB05 5.4 · IC025 +2.3
3/3 methods agree
Reporting / coding artifact85% consumernot reported in cached trials
Glycosylated haemoglobin abnormal657.5
5.9–9.7ROR 7.5 · calibrated p 0.084
6.9 EB05 5.6 · IC025 +2.4
3/3 methods agree
Lab value / disease markerserious n=11 · 91% consumerNCT04255433: 4/6,647 (0.1%) on Tirzepatide (serious AE)
Sleep disorder due to general medical condition, insomnia type3447.3
6.6–8.2ROR 7.3 · calibrated p 0.087
6.9 EB05 6.3 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=74 · 96% consumernot reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Pancreatitis1,9013.13.0–3.3signal
Hypoglycaemia1,8812.62.5–2.7signal
Hyperglycaemia / diabetes3,4161.31.2–1.3raised
Depression1,9510.90.9–0.9lower than other drugs
Anaphylaxis / angioedema5290.50.5–0.6lower than other drugs
Liver injury8820.40.4–0.4lower than other drugs
Kidney injury1,1320.30.3–0.3lower than other drugs
Arrhythmia / qt4180.30.3–0.3lower than other drugs
Tendon disorder800.30.2–0.3lower than other drugs
Suicidality5140.30.2–0.3lower than other drugs
Venous thromboembolism4520.30.2–0.3lower than other drugs
Opportunistic infection2640.30.2–0.3lower than other drugs
Gi bleeding3450.20.2–0.3lower than other drugs
Fall / fracture6800.20.2–0.2lower than other drugs
Hyponatraemia1310.20.2–0.3lower than other drugs
Serious infection1,2210.20.2–0.2lower than other drugs

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Tirzepatide as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (16 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Incorrect dose administered29,67219.7
19.5–19.9ROR 24.0 · calibrated p 8e-4 ✓
17.2 EB05 17.1 · IC025 +4.1
3/3 methods agree
Reporting / coding artifactage-adj. PRR 26.1 · serious PRR 2.4 · 97% consumernot reported in cached trials
Nausea17,0922.9
2.8–2.9ROR 3.1 · calibrated p 0.597
2.8 EB05 2.8 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.3 · serious PRR 3.4 · 93% consumerNCT04255433: 5/6,647 (0.1%) on Tirzepatide (serious AE)
Diarrhoea (diarrhea)10,0062.0
2.0–2.1ROR 2.1 · calibrated p 0.994
2.0 EB05 2.0 · IC025 +1.0Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 3.2 · 92% consumerNCT04255433: 13/6,647 (0.2%) on Tirzepatide (serious AE)
Extra dose administered9,60841.3
40.3–42.2ROR 43.8 · calibrated p 3e-5 ✓
31.4 EB05 30.9 · IC025 +4.9
3/3 methods agree
Not in label — unassessedage-adj. PRR 59.5 · serious n=142 · 97% consumernot reported in cached trials
Off label use (used outside approved label)8,9411.3
1.3–1.4ROR 1.4 · calibrated p 0.554
1.3 EB05 1.3 · IC025 +0.4Reporting / coding artifactage-adj. PRR 1.5 · serious PRR 1.4 · 92% consumernot reported in cached trials
Vomiting8,2672.3
2.3–2.4ROR 2.4 · calibrated p 0.858
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 1.9 · serious PRR 4.3 · 90% consumerNCT04255433: 20/6,647 (0.3%) on Tirzepatide (serious AE)
Drug ineffective (drug did not work)6,9650.7
0.7–0.7ROR 0.7 · calibrated p 0.118
0.7 EB05 0.7 · IC025 -0.6
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.7 · serious PRR 0.4 · 94% consumernot reported in cached trials
Constipation6,5024.0
3.9–4.1ROR 4.1 · calibrated p 0.352
3.9 EB05 3.8 · IC025 +1.9
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 3.6 · serious PRR 5.3 · 95% consumerNCT04255433: 8/6,647 (0.1%) on Tirzepatide (serious AE)
Fatigue (tiredness)4,7710.8
0.8–0.8ROR 0.8 · calibrated p 0.180
0.8 EB05 0.8 · IC025 -0.4
PRR-only: not supported by EBGM or IC
Not in label — unassessedage-adj. PRR 0.7 · serious PRR 1.2 · 93% consumerNCT04255433: 4/6,647 (0.1%) on Tirzepatide (serious AE)
Accidental underdose4,60960.3
58.3–62.5ROR 62.1 · calibrated p 3e-6 ✓
41.3 EB05 40.3 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=25 · 98% consumernot reported in cached trials
Product dose omission issue4,4742.1
2.0–2.1ROR 2.1 · calibrated p 0.997
2.1 EB05 2.0 · IC025 +1.0
3/3 methods agree
Reporting / coding artifactage-adj. PRR 2.7 · serious PRR 2.1 · 94% consumernot reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Tirzepatide?

In FDA FAERS, the most frequently co-reported reaction terms for Tirzepatide are nausea, injection site pain, diarrhoea, extra dose administered, vomiting, constipation. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Tirzepatide have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: RISK OF THYROID C-CELL TUMORS In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO ca.

Do FAERS signals prove that Tirzepatide causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.